PainReform Ltd. (NASDAQ:PRFX) Sees Significant Decline in Short Interest

PainReform Ltd. (NASDAQ:PRFX) saw a significant decline in short interest in the month of February. As of February 27th, there was short interest totaling 78,499 shares, a decline of 64.6% from the February 12th total of 221,954 shares. Based on an average daily trading volume, of 66,985 shares, the days-to-cover ratio is currently 1.2 days. Currently, 29.7% of the company’s shares are sold short. Currently, 29.7% of the company’s shares are sold short. Based on an average daily trading volume, of 66,985 shares, the days-to-cover ratio is currently 1.2 days.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of PainReform in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

PainReform Stock Performance

Shares of PRFX stock traded down $0.06 during trading hours on Friday, reaching $2.78. The company had a trading volume of 21,075 shares, compared to its average volume of 49,186. PainReform has a twelve month low of $2.50 and a twelve month high of $17.95. The company has a market capitalization of $1.11 million, a P/E ratio of 0.00 and a beta of 0.55. The stock’s fifty day simple moving average is $3.46 and its 200 day simple moving average is $4.97.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.